BRITEPath- Phase 2
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Depression
- Suicidal Ideation
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study will use a parallel study design, where participants are randomized into two groups, BRITEPath or TAU, and will receive interventions in parallel.Masking: Single (Outcomes Assessor)Masking Description: Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 12 years and 26 years
- Gender
- Both males and females
Description
BRITEPath has 3 components: 1) BRITE, an emotion regulation and safety planning phone app that is delivered by a co-located mental health (MH) clinician to adolescents at the time of their first therapy appointment; 2) Guide2Brite, which will guide the co-located MH clinician in working with the ado...
BRITEPath has 3 components: 1) BRITE, an emotion regulation and safety planning phone app that is delivered by a co-located mental health (MH) clinician to adolescents at the time of their first therapy appointment; 2) Guide2Brite, which will guide the co-located MH clinician in working with the adolescent to population content onto BRITE; and 3) BRITEBoard, which is a clinician dashboard delivered to the MH clinician and PCP. Assignment of Interventions: This study will utilize a 1:1 randomization scheme to randomize participants to receive BRITEPath intervention or Treatment as Usual (TAU). Hypothesis: The use of BRITEPath will decrease depressive symptoms, distress, and suicidality (any self-injurious ideation, urges, or behavior) as well as improve overall functioning compared to TAU.
Tracking Information
- NCT #
- NCT04672798
- Collaborators
- Kaiser Foundation Research Institute
- National Institute of Mental Health (NIMH)
- Investigators
- Principal Investigator: Stephanie Stepp, PhD University of Pittsburgh Study Director: David Brent, MD University of Pittsburgh
Get Well Soon